Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

(2019) Luigi Formisano et al.   Nature Communications

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

(2019) Nicholas C. Turner et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer

(2019) Mohamed Elbadawy et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy

(2019) Nadiia Lypova et al.   Cancers

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

(2019) Sobhani et al.   Cells

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

(2019) Anna E. Vilgelm et al.   Science Translational Medicine

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

(2019) Concepción Sánchez-Martínez et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer

(2018) P Mao et al.   CANCER RESEARCH

TERT regulates telomere-related senescence and apoptosis through DNA damage response in male germ cells exposed to BPDE in vitro and to B[ a ]P in vivo

(2018) Xi Ling et al.   ENVIRONMENTAL POLLUTION

Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells

(2018) Priyank Patel et al.   MOLECULAR CANCER RESEARCH

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

(2018) Jessica L.F. Teh et al.   CLINICAL CANCER RESEARCH

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

(2018) Kamal Pandey et al.   INTERNATIONAL JOURNAL OF CANCER

Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations

(2018) Liqun Yu et al.   CANCER LETTERS

Differential impact of RB status on E2F1 reprogramming in human cancer

(2017) Christopher McNair et al.   JOURNAL OF CLINICAL INVESTIGATION

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition

(2017) Míriam Tarrado‐Castellarnau et al.   Molecular Systems Biology

MYC Modulation around the CDK2/p27/SKP2 Axis

(2017) Per Hydbring et al.   Genes

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Ablation of human telomerase reverse transcriptase (hTERT) induces cellular senescence in gastric cancer through a galectin-3 dependent mechanism

(2016) Sun-Hyuk La et al.   Oncotarget

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

(2016) Luca Malorni et al.   Oncotarget

Cdk2: a key regulator of the senescence control function of Myc

(2016) Per Hydbring et al.   Aging-US

RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer

(2015) Erik S Knudsen et al.   CELL CYCLE

Endocrine resistance in breast cancer – An overview and update

(2015) Robert Clarke et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

(2015) Christopher D. Hart et al.   Nature Reviews Clinical Oncology

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

(2015) Barbie Taylor-Harding et al.   Oncotarget

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary Gland

(2011) X. Wang et al.   CANCER RESEARCH

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

(2011) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Tipping the Balance: Cdk2 Enables Myc to Suppress Senescence

(2010) P. Hydbring et al.   CANCER RESEARCH

Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation

(2009) P. Hydbring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

(2008) Sherene Loi et al.   BMC GENOMICS